Tubize-Fin Asset Resilience Ratio
Tubize-Fin asset resilience ratio. Tubize-Fin (TUB) has an Asset Resilience Ratio of 2.50% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Tubize-Fin liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Tubize-Fin (2002–2025)
Asset resilience ratio of Tubize-Fin from 2002 to 2025. This chart shows how Tubize-Fin's Asset Resilience Ratio has changed over time. Read Tubize-Fin total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Tubize-Fin's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TUB current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €49.75 Million | 2.5% |
| Total Liquid Assets | €49.75 Million | 2.50% |
Asset Resilience Insights
- Limited Liquidity: Tubize-Fin maintains only 2.50% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tubize-Fin Industry Peers by Asset Resilience Ratio
Compare Tubize-Fin's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 78.22% |
Tubize-Fin Asset Resilience Ratio by Year (2002–2025)
Tubize-Fin asset resilience ratio by year from 2002 to 2025. The table below shows the annual Asset Resilience Ratio data for Tubize-Fin.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.05% | €900.00K ≈ $1.05 Million |
€1.93 Billion ≈ $2.26 Billion |
-46.12pp |
| 2021-12-31 | 46.17% | €1.51 Billion ≈ $1.76 Billion |
€3.27 Billion ≈ $3.82 Billion |
+43.14pp |
| 2013-12-31 | 3.03% | €54.65 Million ≈ $63.90 Million |
€1.80 Billion ≈ $2.11 Billion |
+2.43pp |
| 2004-12-31 | 0.60% | €4.30 Million ≈ $5.03 Million |
€715.25 Million ≈ $836.21 Million |
+0.54pp |
| 2003-12-31 | 0.06% | €500.00K ≈ $584.55K |
€791.03 Million ≈ $924.80 Million |
-0.01pp |
| 2002-12-31 | 0.07% | €530.00K ≈ $619.63K |
€748.11 Million ≈ $874.61 Million |
-- |
About Tubize-Fin
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.